Skip to content
NASDAQ · FINANCE SERVICES · SMALL CAP

TAO Synergies Inc. TAOX

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$299,061
$-28.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We are principally focused on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. We are also evaluating Bryostatin-1 for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome and Multiple Sclerosis, which have undergone pre-clinical testing. On June 9, 2025, in connection with our previously announced exploration of strategic opportunities, we announced the launch of a differentiated cryptocurrency treasury strategy focused on the pure play artificial intelligence (AI) crypto coin, TAO, the native cryptocurrency of Bittensor, a decentralized blockchain network for machine learning and AI.

Written from the business description in TAO Synergies Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth

USD 299,061.00
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.3 · Net income -28.7
-15M-30M
201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2025 · ROE -213.5%
-100%-200%
201920222025
Three returns, three denominators.

Each USD of equity lost 214 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -5.2
-5M-10M
201920222025

Total assetsUSD 25.8M
EquityUSD 21.1M
CashUSD 5.5M
Current ratio13.99×

Equity funds 81% of total assets.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
TAOX, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B0.00.0◌◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0◌
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0◌
Income tax $B0.00.00.0◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌◌−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−8.81−10.9929.56−0.81−2.5112.033.01
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %−213.5−84.5−21.2−16.8−65.2−112.6−86.9
Shares out B0.010.000.020.010.010.01◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 2 failures in 28 reconciliationsAUDITED

Reconciled in 5 of the 7 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 17 checks were skipped: revenue is not tagged before 2024. 12 checks were skipped: EPS is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency2 failures
ActivityFinance Services
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019

Share this section

Download image